Literature DB >> 24927311

A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom.

D Taylor Shubhra Mace Shameem Mir Robert Kerwin.   

Abstract

OBJECT: Available efficacy data for atypical antipsychotics relate almost entirely to the use of atypicals alone. Previous surveys have, however, shown that typical antipsychotics are often co-prescribed alongside atypical drugs. We sought to evaluate prescribing of atypical antipsychotics to inpatients during one week of June 1998.
METHOD: Requests for information were sent out to 229 UK centres which employed psychiatric pharmacists. From these, 143 (62%) responses were received, providing information on 3685 patients prescribed atypical antipsychotics. Data on patients prescribed an atypical for longer than 6 weeks were used as the primary indicator of prescribing practice.
RESULTS: For all atypicals examined, co-prescription of typical drugs was commonplace. The proportions of patients receiving an atypical as the sole antipsychotic were: clozapine 56.5%, risperidone 27.6%, sertindole 27.1%, olanzapine 18.9%, quetiapine 9.7% and amisulpride 7.1%. Patients prescribed regular typical antipsychotics alongside atypical drugs were significantly more likely to be prescribed regular anticholinergic medication, indicating higher rates of acute extrapyramidal effects in those receiving antipsychotic polypharmacy. Atypical antipsychotics were prescribed alone in a minority of patients.
CONCLUSIONS: Whilst there is some support for antipsychotic polypharmacy in certain cases, judging by strict evidence-based criteria the prescribing of atypical antipsychotics in our survey was poor. (Int J Psych Clin Pract 2000; 4:41-46).

Entities:  

Keywords:  Antipsychotics Polypharmacy Cost-EFFECTIVENESS Prescribing Anticholinergics

Year:  2000        PMID: 24927311     DOI: 10.1080/13651500052048749

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   1.812


  10 in total

1.  Atypical antipsychotics in the treatment of schizophrenia. Users' experiences of treatments must be considered.

Authors:  C Prior ; J Clements; M Rowett
Journal:  BMJ       Date:  2001-04-14

Review 2.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

3.  Safety and tolerability of antipsychotic polypharmacy.

Authors:  Juan A Gallego; Jimmi Nielsen; Marc De Hert; John M Kane; Christoph U Correll
Journal:  Expert Opin Drug Saf       Date:  2012-05-08       Impact factor: 4.250

4.  Antipsychotic Use Pattern in People with Psychotic Disorder Living in Board and Care Facilities.

Authors:  Etem Erdal Ersan; Mustafa Yildiz
Journal:  Noro Psikiyatr Ars       Date:  2015-06-01       Impact factor: 1.339

5.  Polypharmacy in the management of patients with schizophrenia on risperidone in a tertiary-care hospital in Malaysia.

Authors:  Sa Jacob; Mi Mohamed Ibrahim; F Mohammed
Journal:  Ment Health Fam Med       Date:  2013-01

Review 6.  Ziprasidone in the management of schizophrenia : the QT interval issue in context.

Authors:  David Taylor
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 7.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Authors:  Christoph U Correll; Juan A Gallego
Journal:  Psychiatr Clin North Am       Date:  2012-07-24

8.  A study of an antipsychotic prescription pattern of patients with schizophrenia in a developing country.

Authors:  Smitha Ramadas; Praveenlal Kuttichira; T P Sumesh; Shijin A Ummer
Journal:  Indian J Psychol Med       Date:  2010-01

9.  Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process.

Authors:  Giouliana Kadra; Robert Stewart; Hitesh Shetty; Richard G Jackson; Mark A Greenwood; Angus Roberts; Chin-Kuo Chang; James H MacCabe; Richard D Hayes
Journal:  BMC Psychiatry       Date:  2015-07-22       Impact factor: 3.630

10.  Socioeconomic status and prescribing for schizophrenia: analysis of 3200 cases from the Glasgow Psychosis Clinical Information System (PsyCIS).

Authors:  Daniel J Martin; John Park; Julie Langan; Moira Connolly; Daniel J Smith; Mark Taylor
Journal:  Psychiatr Bull (2014)       Date:  2014-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.